Cantor Fitzgerald Believes Biohaven Pharmaceutical Holding Co Ltd (BHVN) Won’t Stop Here


Cantor Fitzgerald analyst Charles Duncan maintained a Buy rating on Biohaven Pharmaceutical Holding Co Ltd (BHVN) today and set a price target of $82. The company’s shares opened today at $49.99, close to its 52-week high of $50.57.

Duncan wrote:

“We rate BHVN Overweight. For the next ~12 mos, we see Biohaven’s rimegepant in acute migraine as the key driver of shareholder value. Valuation Summary We use a discounted NPV revenue calculation that yields ~$72 for rime’ in acute migraine, and ~$11 for pipeline placeholders. The Disclosure Section may be found on pages 3 – 4.Valuation In valuing BHVN, we used a discounted NPV revenue calculation that yields ~$47 for rime’ in acute migraine and ~$18 for pipeline placeholders ($750M total NPV for rime’ in preventative migraine, ‘3500 in acute migraine and glutamate platform candidates).”

According to TipRanks.com, Duncan is a 3-star analyst with an average return of 2.5% and a 48.0% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals Inc, KalVista Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.

Biohaven Pharmaceutical Holding Co Ltd has an analyst consensus of Strong Buy, with a price target consensus of $64, implying a 28.0% upside from current levels. In a report issued on March 3, Oppenheimer also maintained a Buy rating on the stock with a $54 price target.

See today’s analyst top recommended stocks >>

Based on Biohaven Pharmaceutical Holding Co Ltd’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $54.62 million. In comparison, last year the company had a GAAP net loss of $27.08 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts